Nigeria-EU Health Investment Forum
About the event
Why this forum matters
Nigeria and West Africa stand at a decisive moment. For decades, our health systems have depended on fragile global supply chains, with up to 80% of medicines and health products imported. The pandemic exposed the risks: shortages, inequities, and lost lives. But it also sparked a new resolve to build health sovereignty by producing what we need, where we need it, for our own people.
Today, that vision is becoming reality. The Presidential Initiative on Unlocking the Healthcare Value Chain (PVAC), with the support of the European Union’s Team Europe Initiative on Manufacturing and Access to Vaccines, Medicines and Health Technologies (MAV+), is transforming Nigeria’s pharmaceutical landscape.
participants
0
+
countries
0
+
health investors
0
+
organisations
0
+
The forum in focus
On 30 October 2025, leaders from government, industry, research, and finance will gather in Abuja for a milestone event hosted by the EU Delegation to Nigeria and ECOWAS, PVAC, and the National Institute for Pharmaceutical Research and Development (NIPRD).
This Health Investment Forum will:
Announce the signing of MAV+ contracts in Nigeria.
Mobilise new investment partnerships for local manufacturing.
Launch a regional agreement with West African Health Organisation (WAHO) to expand maternal and reproductive health access.
Deliver a shared roadmap for long-term sustainability.
Theme:
Made in Nigeria.
Made for Health.
This theme reflects a collective determination to build strong, self-reliant, and sustainable health systems that protect lives, strengthen economies, and drive inclusive growth.
What participants can expect
Policy showcase:
Progress under PVAC and MAV+, aligned with the EU’s Global Gateway strategy.
Deal-making space:
Business-to-business sessions linking pharmaceutical companies with financiers, donors, and regulators.
Commitment to equity:
Regional momentum to expand access to Sexual and Reproductive Health and Rights (SRHR) products and services, addressing a maternal mortality rate still five times above global targets.
Deal-making space:
Business-to-business sessions linking pharmaceutical companies with financiers, donors, and regulators.
Innovation for sustainability:
Dialogue on climate-smart, low-carbon pharmaceutical production
Why it matters for the region
This forum is more than an event. It is a turning point. By investing in local pharmaceutical manufacturing, Nigeria and its partners are laying the foundation for stronger public health, reduced dependence on imports, and a resilient regional value chain. It represents a powerful convergence of health equity, economic development, and environmental sustainability.
Structured around policy dialogue, and investment mobilisation, the forum will:
- Frame expectations: What do stakeholders seek to achieve?
- Discuss challenges: What obstacles can be tackled collectively within and outside the health ecosystem?
- Identify the way forward: What agreements and follow-up actions are required?
Target audience
Government
Federal Government of Nigeria (Presidency, Ministers, Regulators).
European Union
EU officials, Delegation representatives, and EU Member States.
Finance
European Investment Bank (EIB) and other Development Finance Institutions.
Private sector
Pharmaceutical Chief Executive Officers, health technology innovators, and investors.
Development partners
Development partners will include WHO, UNFPA, UNICEF, GIZ, and USAID.
Knowledge and accountability actors
Academia, civil society, and media representatives.